The biopsied samples of patients with cancer (glioma, lung cancer, pancreatic cancer, thyroid cancer, mantle cell lymphoma, B-cell non-Hodgkin lymphoma, and human melanoma) showed an increased quantity of CB1 and CB2 receptors. This evidence concerns the gene CNR1 and glioma.